Adipotide (Prohibitin-TP01) / Arrowhead - LARVOL DELTA

Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity. (PubMed, J Am Chem Soc) - "The most potent compound, PTP-r, was prohibitin-TP01 substituted with d-arginine. Overall, the study reveals the promising development of next-generation adipose-targeting prohibitin peptides, capable of curbing adipocyte expansion and body weight, with favorable preclinical safety profiles. These peptides hold immense potential for developing new treatments to address obesity and metabolic syndrome."

Journal • Preclinical • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity (clinicaltrials.gov) - P1; N=4; Terminated; Sponsor: M.D. Anderson Cancer Center; Trial completion date: May 2020 ➔ Jan 2019; Active, not recruiting ➔ Terminated; Trial primary completion date: May 2019 ➔ Jan 2019; Terminated per PI's request

Clinical • Trial completion date • Trial primary completion date • Trial termination • Genetic Disorders • Genito-urinary Cancer • Obesity • Oncology • Prostate Cancer • Solid Tumor

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity (clinicaltrials.gov) - P1; N=4; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Trial primary completion date: May 2018 ➔ May 2019

Trial primary completion date • Biosimilar • Genito-urinary Cancer • Obesity • Oncology • Prostate Cancer • Solid Tumor